KRAS G 12C -inhibitor-based combination therapies for pancreatic cancer: insights from drug screening.

MLA

Tapia Contreras, Constanza, et al. “KRAS G 12C -Inhibitor-Based Combination Therapies for Pancreatic Cancer: Insights from Drug Screening.” Molecular Oncology, Sept. 2024. EBSCOhost, https://doi.org/10.1002/1878-0261.13725.

APA

Tapia Contreras, C., Falke, J. D., Seifert, D.-M., Schneider, C., Krauß, L., Fang, X., Müller, D., Demirdizen, E., Spitzner, M., De Oliveira, T., Schneeweis, C., Gaedcke, J., Kaulfuß, S., Mirzakhani, K., Wollnik, B., Conrads, K., Beißbarth, T., Salinas, G., Hügel, J., … Schneider, G. (2024). KRAS G 12C -inhibitor-based combination therapies for pancreatic cancer: insights from drug screening. Molecular Oncology. https://doi.org/10.1002/1878-0261.13725

Chicago

Tapia Contreras, Constanza, Jonas Dominik Falke, Dana-Magdalena Seifert, Carolin Schneider, Lukas Krauß, Xin Fang, Denise Müller, et al. 2024. “KRAS G 12C -Inhibitor-Based Combination Therapies for Pancreatic Cancer: Insights from Drug Screening.” Molecular Oncology, September. doi:10.1002/1878-0261.13725.